US OptionsDetailed Quotes

BEAM250516P30000

Watchlist

16.39
0.000.00%

15min DelayClose May 1 15:59 ET

0.00High0.00Low

Beam Therapeutics Stock Discussion

70107480

Apr 18 02:37

$Beam Therapeutics (BEAM.US)$
Its just a ticking time bomb, just a matter of time.

Teddy123

Apr 6 13:28

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

$Beam Therapeutics (BEAM.US)$
Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment

Trytosaveabit

Mar 28 04:03

news

$Beam Therapeutics (BEAM.US)$ Reuters· 1 min ago
Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd) by the United States (U.S.) Food and Drug Administration

MrJav

Mar 27 19:49

$Beam Therapeutics (BEAM.US)$ why id this going down?, is there going to ve any big movements any time soon?

10baggerbamm

Mar 11 15:43

$Nasdaq Composite Index (.IXIC.US)$ Cathy Woods Ark Purchases yesterday $Tesla (TSLA.US)$ $Advanced Micro Devices (AMD.US)$ $Palantir (PLTR.US)$ $Coinbase (COIN.US)$ $Robinhood (HOOD.US)$ $Beam Therapeutics (BEAM.US)$ $Shopify (SHOP.US)$ $Tempus AI (TEM.US)$ $Recursion Pharmaceuticals (RXRX.US)$

Smokey The Bear

Mar 10 18:53

$Beam Therapeutics (BEAM.US)$ she a 🏃‍♀️ she 👣 🌟 🤩

Teddy123

Mar 10 18:29

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causin

$Beam Therapeutics (BEAM.US)$
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Moomoo News Global

Feb 21 20:16

Columns HIMS Jumps 174% YTD — Who's Next?

$Hims & Hers Health (HIMS.US)$ , an online health and wellness platform, has seen its stock soar over 78% since February, with a year-to-date surge exceeding 174%. This outpaces the projected full-year gain of 171% for 2024.
What's Fueling HIMS' Rally?
HIMS surged 17.5% on Wednesday following the announcement of an acquisition, reaching an intraday high of nearly 25% and hitting a record $72.
Hims & Hers disclosed it acquired Sigmund NJ LLC, also known as Trybe La...

Analysts Notebook

Feb 13 19:50

Columns Interest in AI-Powered MedTech is on the Rise: Key Stocks to Watch

The attention of AI Medteck stocks are rapidly increasing.
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...

116

285

Moomoo News Global

Feb 6 17:43

Columns AI Healthcare-tech May Be the Next Big Thing. Here's Why

US Congress member Nancy Pelosi and Ark Invest's Cathie Wood both bet big on an AI stock recently.
The stock in question is $Tempus AI (TEM.US)$, a company that uses data and artificial intelligence (AI) to create precision medicine services. ARK Invest, a prominent advocate for innovative technologies, first showed interest on December 6, when it purchased shares in this healthcare technology firm. Since that initial investment, Tempus AI h...

154

No comment yet